Dexcom (DXCM) Operating Leases (2019 - 2026)

Dexcom (DXCM) has reported Operating Leases for 8 consecutive years, with $82.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases rose 51.01% year-over-year to $82.6 million in Q2 2026; TTM through Jun 2026 was $82.6 million, a 51.01% increase from a year earlier, with the FY2025 full-year figure at $73.4 million, up 12.92% from the prior year.
• Operating Leases was $82.6 million for Q2 2026 at Dexcom, up from $69.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $94.6 million in Q4 2022 and troughed at $50.6 million in Q3 2025.
• A 5-year average of $76.5 million and a median of $78.4 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases declined 28.83% in 2025 and jumped 51.01% in 2026, its largest moves.
• Over 5 years, Operating Leases stood at $94.6 million in 2022, then decreased by 15.33% to $80.1 million in 2023, then declined by 18.85% to $65.0 million in 2024, then rose by 12.92% to $73.4 million in 2025, then grew by 12.53% to $82.6 million in 2026.
• The last three Operating Leases figures came in at $82.6 million (Q2 2026), $69.0 million (Q1 2026), and $73.4 million (Q4 2025), per Business Quant data.